The safety and science of a 2-chamber nitric oxide activating serum.
This is part 2 in a 2-part series
N101 Activating Skincare Serum (Pneuma Nitric Oxide, Austin, Tex.) is a patent-pending dual chamber nitric oxide activating serum.
“When you apply one drop out of each chamber and mix the two together on the skin, it generates nitric oxide,” says Dr. Chernoff.
Notably, in his studies, nitric oxide levels of more than 15,000 ppb were detected during serum mixing of the two serums from separate product chambers and nitric oxide was still detected on the skin 30 minutes after application, overall demonstrating normal decay kinetics.
“It's very dramatic when you put it on because once you apply it, for the 15 to 30 minutes you get extreme basal dilation. So, it's a product where you can actually see its benefits,” says Dr. Chernoff.
And while study results show skin feature improvements, it’s not simply a replacement product in the skincare regime, says Dr. Chernoff.
“It's a vehicle that helps whatever else you're putting on your skin to get absorbed better,” he says.
The first part of the study was a safety analysis, says Dr. Chernoff. Patients applied the nitric oxide serum to one half of their face and a glycerin placebo to the other half.
“We found no adverse effects or hypersensitivity reactions with the product due to tremendous anti-inflammatory effects,” he says.
Dr. Chernoff believes this is just the beginning of what’s to come with this molecule in aesthetics.
“It's been shown again that nitric oxide plays a vital role in the enzymatic reactions of stem cell communication as well, so I really think medicine is going to change a lot in the next 5 to 10 years where we will see cellular medicine [and] regenerative therapies that have definitive basis, come to play for patients.”
Chernoff G. The Utilization of a Topical Nitric Oxide Generating Serum in the Aging Skin Population: A Pilot Study. Ann Plast Reconstr Surg. 2020; 4(2): 1053.
Chernoff G. The Utilization of a Nitric Oxide Generating Serum in the Treatment of Active Acne and Acne Scarred Patients. Int J Pharma Anal Acta. 2020;3(1): 010-014.